Evidence map›Paper›PMID 34463708›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Envisioning Future Urinary Tract Infection Diagnostics.

Robin Patel, Christopher R Polage, Jennifer Dien Bard, Larissa May, Francesca M Lee, Valeria Fabre, Mary K Hayden, Sarah D B Doernberg, David A Haake, Barbara W Trautner and 3 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Clinical application of MALDI-TOF MS for direct and rapid pathogen identification: a comprehensive review focusing on bloodstream infections and sterile body fluids.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Robin PatelDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141
Christopher R PolageDepartment of Pathology, Duke University Health System, Durham, North Carolina, USA.
Jennifer Dien BardDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Larissa MayDepartment of Emergency Medicine, University of California-Davis Health, Sacramento, California, USA.
Francesca M LeeDivision of Infectious Diseases, Department of Pathology and Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Valeria FabreDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mary K HaydenDivision of Infectious Diseases, Division of Internal Medicine, Rush Medical College, Chicago, IL, USA.
Sarah D B DoernbergDivision of Infectious Disease, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
David A HaakeInfectious Diseases Section, VA Greater Los Angeles Healthcare System, and the Division of Infectious Diseases, Department of Medicine, the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Barbara W TrautnerCenter for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Larissa GrigoryanCenter for Innovation in Quality Effectiveness and Safety, Michael E. DeBakay Veterans Affairs Medical Centetr; and and 15 Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas, USA.
Ephraim L TsalikDuke University Center for Applied Genomics and Precision Medicine, Durham, NC, USA; Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.
Kimberly E HansonDepartment of Internal Medicine and Department of Pathology, University of Utah, Salt Lake City, Utah, USA.

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

Urinary tract infections (UTIs) are among the most common bacterial infections in the United States and are a major driver of antibiotic use, both appropriate and inappropriate, across healthcare settings. Novel UTI diagnostics are a strategy that might enable better UTI treatment. Members of the Antibacterial Resistance Leadership Group Laboratory Center and the Infectious Diseases Society of America Diagnostics Committee convened to envision ideal future UTI diagnostics, with a view towards improving delivery of healthcare, patient outcomes and experiences, and antibiotic use, addressing which types of UTI diagnostics are needed and how companies might approach development of novel UTI diagnostics.

Indexed as

Urinary Tract InfectionsAnti-Bacterial AgentsDrug Resistance, BacterialHumansUnited StatesAnti-Bacterial Agentsdiagnosticslaboratory diagnosisurinary tract infectionUTI

Identifiers

PMID34463708
PMCPMC8994576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.